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Abstract
Current treatment options for debilitating bone diseases such as osteosarcoma, osteoporosis, and
bone metastatic cancer are suboptimal and have low efficacy. New treatment options for these
pathologies require targeted therapy that maximizes exposure to the diseased tissue and minimizes
off-target side effects. This work investigates an approach for generating functional and targeted
drug carriers specifically for treating primary osteosarcoma, a disease in which recurrence is
common and the cure rate has remained around 20%. Our approach utilizes the modularity of
Layer-by-Layer (LbL) assembly to generate tissue-specific drug carriers for systemic
administration. This is accomplished via surface modification of drug-loaded nanoparticles with
an aqueous polyelectrolyte, poly(acrylic acid) (PAA), side-chain functionalized with alendronate,
a potent clinically-used bisphosphonate. Nanoparticles coated with PAA-Alendronate are
observed to bind and internalize rapidly in human osteosarcoma 143B cells. Encapsulation of
doxorubicin, a front-line chemotherapeutic, in an LbL-targeted liposome demonstrates potent
toxicity in vitro. Active targeting of 143B xenografts in NCR nude mice with the LbL-targeted
doxorubicin liposomes promotes enhanced, prolonged tumor accumulation and significantly
improved efficacy. This report represents a tunable approach towards the synthesis of drug
carriers, in which LbL can enable surface modification of nanoparticles for tissue-specific
targeting and treatment.
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1. Introduction
The development, maintenance, and repair of bone require cell-mediated remodeling to
sustain the structural integrity of the tissue. Disturbances in the physiological processes of
osteoblast-mediated bone deposition and osteoclast-mediated bone resorption are observed
in many bone-related disease states, such as osteosarcoma, cancer metastasis to bone,
osteoporosis, and Paget’s disease of the bone.[1] Several therapies have been developed to
combat these pathologies;[1–2] however, the clinical outcomes for patients with these
diseases continue to be very poor. The arsenal of available agents to treat patients has not
made any substantial impact in improving their survival, and new methods for therapy are
critical. Engineering a robust delivery platform with bone-tissue level specificity to treat
these diseases can improve therapeutic efficacy, lower systemic toxicity, and improve
disease management.
Significant fundamental work in the area of bone biology has uncovered the potential of
bone-specific agents, such as bisphosphonates.[2b, 3] These compounds act as
pharmacophores, whereby the pyrophosphate-like structure coordinates calcium ions within
the hydroxyapatite mineral in bone with high affinity and specificity. Accumulation of
bisphosphonates further promotes inhibition of bone resorption by inducing apoptosis in
osteoclasts that are responsible for this action. As such, this class of pharmaceutics is a
potent drug for promoting homeostasis between osteoclast and osteoblast activity in, for
example, osteoporosis, while also promoting tissue-specific binding and localization.
Bone targeting systems[4] have been synthesized to utilize the specificity of a variety of
ligands, including bisphosphonates, tetracycline and derivatives, sialic acid, and bio-inspired
materials containing similar functionalities[2b]; however, systems capable of therapeutic
delivery for treatment of bone-related diseases remain limited. Towards this end, the
modularity of Layer-by-Layer (LbL)-functionalized nanomedicine systems[5] presents an
attractive opportunity to incorporate these bone-specific, highly water-soluble ligands on the
surface of nanotechnology for targeted drug delivery. LbL assembly[6] is a highly controlled
approach to iteratively deposit materials and functionalize the surface of virtually any
substrate on the basis of complementary interactions, such as electrostatics. This method
allows for tunable, nanoscale precision over system design, allowing for the construction of
a customizable therapeutic delivery platform[5i, 7]. Recent work has demonstrated the
potential for LbL nanoparticle systems to promote improved pharmacokinetics and
biodistribution of the carrier and drug in vivo,[8] with the ability to modulate release of
encapsulated therapeutics. Complementary studies investigated tumor microenvironment
cue-sensitive designs (e.g. pH-responsive[9]) that harnessed tumor hypoxia to promote
enhanced localization and uptake in tumors. Further, these built-to-order systems have been
recently manufactured on a scalable platform[10], demonstrating potential to mass-produce
these systems with high levels of control.
In this study, we report the synthesis of tissue-targeted LbL nanoparticles, specifically
manufactured to hone in on bone tissue. To achieve this, a polyelectrolyte, poly(acrylic acid)
(PAA), was functionalized with a bisphosphonate, alendronate, and subsequently
electrostatically-assembled in a nanoparticle coating. The functionalized particles
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accumulated in subcutaneous 143B osteosarcoma xenografts, where they delivered their
payload, doxorubicin, in a mouse model. The targeted particles significantly attenuated
tumor burden and extended animal survival, in some cases even completely eliminating
tumors. The results described herein establish LbL as a modular approach to develop
targeted drug carriers via adsorption of ligand-functionalized, aqueous polyelectrolytes for
tissue-specific targeting, further developing these systems towards clinical application.
2. Results and Discussion
LbL-targeted nanoparticle systems were generated by covalent modification of PAA (Mν ~
450K, Figure 1A) with alendronate (Figure 1B) at 40% functionalization of the total
carboxylic groups on the PAA molecule (Figure 1C). Alendronate was coupled via its amino
functional handle to PAA through an amide bond. As both of the components were water
soluble, we used methyl morpholine-based water-soluble coupling agents to perform amide
coupling (Figure S1). The immobilization of the molecule onto the PAA backbone was
confirmed by 31P and 1H NMR. The functionalized PAA-Alendronate polymer was
subsequently used as the polyanionic layer in LbL assembly, iteratively adsorbed on a solid
nanoparticle substrate in alternation with polycationic poly-L-lysine (PLL), as schematically
illustrated in Figure 1D. PAA is a well-characterized[11] weak polyanion with a high charge
density and a non-erodible backbone that has been listed as an approved excipient in the
FDA's Inactive Ingredient Guide and is used in clinically-approved drug formulations as a
stabilizer and thickener to tune the rheological properties of the injectable or topically-
applied therapeutic. As such, PAA presented a suitable material for introducing tissue
specificity and targeting via alendronate functionalization.
To establish these systems as osteotropic delivery systems, initial investigations employed a
25 nm quantum dot (QD) (CdSeTe core) for imaging purposes to understand how the
coating directed particle association with osteosarcoma cells (143B) in vitro and in vivo, as
well as other hard tissue in vivo. These particles were fabricated as shown in Figure 1D, with
linear film growth observed for three bilayers of (PLL/PAA-Alendronate) to a final z-
average hydrodynamic diameter of 115 nm, with a PDI of 0.19, and zeta-potential of −39
mV (10 mM NaCl in DI water, 25°C; Figure S2).
Incubation of LbL-targeted QD705 nanoparticles with 143B cells showed significant binding
and cell uptake after 2 hours at 37°C (see Figure 2A), where red is representative of QD705
nanoparticle fluorescence. Nanoparticle binding, on the basis of QD705 fluorescence, was
further characterized and observed to be dose-dependent for a range of concentrations, over
which little cytotoxicity (48 hour incubation) was observed, as shown in Figure 2B. The
number of bilayers (1, 2, and 3, whereby 1, 2, and 3 layers of the targeted PAA-Alendronate
polymer are incorporated on the particle surface) was also investigated. These results are
shown Figure S3. It was observed that the in vitro binding affinities and cytotoxicity profile
were similar across different bilayer numbers. Previous work[8b] established the improved
biological performance of QD nanoparticles with 3 or more bilayers; therefore, we focused
on the 3-bilayer LbL-targeted QD particles for in vivo assessment of targeting.
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To evaluate this system in vivo, LbL-targeted QD800 nanoparticles were administered via the
tail vein in NCR nude mice with ectopically induced 143B osteosarcoma xenografts. Particle
distribution in live animals was tracked using whole-animal in vivo fluorescence imaging
(Figure 3A). Immediately following administration, the particles rapidly accumulated in the
bone tissue regions, particularly in the parietal region of the cranium, spinal column, and
hind limb regions. At later time points, particles trafficked to the 143B xenografts,
consistent with targeted interactions with the tumor matrix. Controls for uncoated,
untargeted QDs and coated QDs with unconjugated PAA showed no specific affinity for
hard tissue and had little to no accumulation in the xenografts, suggesting the enhanced
permeation and retention effect does not account for much of this tumor localization (Figure
S4). Tumor-specific accumulation was significant and observed over the course of 8 days
(Figure 3B). Such a long period of accumulation may be due to the strong binding affinity
between alendronate and the osteosarcoma tissue, leading to much longer residences times
of the nanoparticle in the tumor. The tumors were resected after 8 days, along with necropsy
of other relevant tissue, and analyzed via recovered fluorescence to investigate post-mortem
particle distribution. Significant localization of particles was observed in xenografts
(accounting for ~30% fluorescence recovered), relative to ~40% in the liver and smaller
fractions in each of the other organs (spleen, kidneys, heart, lungs) harvested (Figure 3C,
Figure S5). Accumulation in the liver is a common challenge for all nanoparticle delivery
platforms, though we have shown in other work that the use of hyaluronic acid can lower
accumulation considerably compared to other systems. Future work will investigate its use
for introducing tissue specificity via ligand functionalization.
To visualize the biodistribution of both the coating and nanoparticle in real time, the
bisphosphonate-targeted polymer, PAA-Alendronate, was labeled with a near-IR, Cy5.5 dye
and adsorbed onto the surface of QD800 to allow for two-color in vivo imaging of the
targeted, 3 bilayer (PLL/PAACy5.5-Alendronate)3 nanoparticle. We observed co-localization
of the two components – the PAA-Alendronate outer layer and the quantum dot - in the
xenografts (Figure 3D, Figure S5) for up to 9 days, further substantiating these systems as
serum-stable targeted platforms for delivery.
Next, we applied the coating, (PLL/PAA-Alendronate), to drug-loaded particle systems for
targeted delivery and treatment of diseased tissue. For this purpose, the coatings were
adapted to a liposomal carrier for use in drug delivery (Figure 4A). Initial work focused on
empty, negatively-charged liposomal carriers, containing DSPC (1,2-distearoyl-sn-
glycero-3-phosphocholine), cholesterol, and POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-(1'-rac-glycerol)), functionalized with one bilayer of PLL/PAA-Al, which yielded
170 nm nanoparticles with a zeta-potential of −20 mV (Figure S6), to validate these systems
for LbL-targeted delivery. Due to size considerations for systemic delivery, fabrication was
truncated after a single bilayer due to the significant increase in size associated with
adsorption of a single bilayer (80–90 nm per bilayer). Differences in bilayer thickness
relative to films on QDs could be due to the relative fluidity of the liposomal substrate.
Consistent with results for the LbL-targeted QDs, binding of the LbL-functionalized
liposomes to 143B cells was observed to be dose-dependent and not apparently cytotoxic
(Figure 4B). Rapid internalization after a 2 hour incubation with the 143B cells, visualized
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by confocal microscopy (Figure 4C) and confirmed via flow cytometry (Figure 4D), was
also observed. The high levels of red, diffuse nanoparticle fluorescence (visualized by
incorporation of PLL-Cy5.5 in the LbL coating), along with a marked shift in cell-associated
fluorescence observed by flow cytometry, suggested this system enabled high levels of
nanoparticle binding and uptake, providing a promising platform for LbL-targeted drug
delivery.
Osteosarcomas are known to be responsive to conventional chemotherapeutics, such as
doxorubicin, so we next explored the incorporation of doxorubicin in the liposomal carrier
for subsequent LbL functionalization. We were able to incorporate doxorubicin into stable
DSPC:Cholesterol:POPG liposomes with high drug-loading efficiency (97%) at 5.5 w/w%
(drug/lipid). During subsequent coating with a single bilayer of (PLL/PAA-Alendronate), no
drug loss was observed, and liposomal morphology remained unchanged, as illustrated in
Figure 4A. The LbL-functionalized doxorubicin-loaded liposome was characterized by a
hydrodynamic diameter of approximately 210 nm in size with a zeta-potential of −20 mV,
measured in 10 mM NaCl (Figure S6). The targeted liposomal carriers were found to be
particularly potent against 143B cells, with high levels of toxicity over a wide-range of
doxorubicin-loaded concentrations following incubation for 24 hours and 48 hours (Figure
4E), whereas the uncoated control showed about 8-fold lower levels of toxicity (Figure 4F).
Translating these systems in vivo, we first investigated the pharmacokinetics of the coated
liposomal system in the absence of drug. Shown in Figure 5A is the circulation profile of
this system on the basis of fluorescence recovery following systemic administration of the
PLL-Cy5.5 labeled carriers to immune-proficient BALB/c mice. Based on a two-
compartment model, the targeted carriers exhibited half-lives of 0.23 hours (fast) and 18.7
hours (slow), indicative of a stable, long-circulating system that could promote enhanced
delivery of loaded therapeutics.
In tumor-bearing NCR nude mice, the same PLL-Cy5.5 labeled, targeted system was
observed to accumulate in the target diseased tissue rapidly, with the ability to persist in the
tumor up to the terminal point of the study - 100 hours (Figure 5B, Figure S7).
Biodistribution results (Figure 5C, Figure S7) at the terminal point of this investigation
further corroborated these systems as stable delivery platforms that preferentially locate in
osteosarcoma xenografts at high levels (~35% on the basis of fluorescence recovery, relative
to ~47% in the liver, ~7% in the kidneys). Elevated amounts of recovered fluorescence in
the liver suggested that hepatic clearance is the primary means of excretion; however, the
large number associated with the liver, in addition to the values reported for other tissue, is
not meant to be wholly quantitative, as the data is reported as percent of the total
fluorescence recovered from only the tissue collected. The relative ratios of fluorescence
between tissue confirmed that we were able to achieve a high level of tumor specificity
relative to the other tissue, which validated this system for further investigation towards
therapeutic delivery.
After observing high levels of tumor localization for the targeted empty liposomal
formulation, the efficacy of the LbL-targeted doxorubicin-loaded liposomes was evaluated
against 143B osteosarcoma xenograft-bearing NCR nude mice. Initial attempts at
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determining the optimal dosing regimen (drug concentration and number/timing of
injections) employed a dose escalation study of serial 1 mg/kg, 2 mg/kg, and 3 mg/kg (based
on doxorubicin loading) injections starting at day 10 post-tumor inoculation with each
treatment separated by one week. As observed in Figure 6A, untreated osteosarcoma tumors
grew beyond terminal size (diameter > 1 cm) after 19 days post-inoculation. Treated mice
for both the uncoated and coated versions survived repeated dosing out to 30 days, after
which comparisons in terminal tumor size were drawn. As observed visually in Figure 6A
and quantified in Figure 6B, LbL-targeted doxorubicin-loaded liposome treated mice
showed significantly reduced terminal tumor sizes relative to the uncoated doxorubicin-
loaded liposome control (characterized by measurements on the longest x-y dimensions).
This observation is consistent with enhancement of the therapeutic potency of the loaded
drug due to preferential accumulation of the targeted system in the 143B xenografts.
Results from the dose escalation study indicated that a higher dose was necessary to
effectively remediate the tumor. For this purpose, LbL-targeted doxorubicin-loaded
liposomes were administered at a doxorubicin concentration of 5 mg/kg, along with an
uncoated, drug-loaded control at the same concentration. Xenograft-bearing mice were
allowed to develop tumors to an area of ~25 mm2 [measured in the longest length and width
dimensions] after which they were treated, with repeated injections one week apart for 3
total treatments until a terminal point at day 40. We observed enhanced efficacy of the LbL-
targeted doxorubicin-loaded liposome, relative to the uncoated control, as determined by
caliper measurements and visual inspection of the terminal point harvested xenografts
(Figure 6C). Varying levels of therapeutic benefit for the targeted group were observed from
complete remediation (NT – no tumor observed) to tumor maintenance (tumor reduction of
30% from day 0 on average), whereas the uncoated control group mice showed significant
tumor growth (several beyond the maximum allowable tumor burden of 1 cm in diameter;
growth of 550% from day 0 on average). These results highlight the capabilities of the LbL-
targeted nanoparticle approach for highly effective chemotherapeutic treatment in tumor-
bearing mice.
Histological analysis via a Masson’s trichrome stain of recovered osteosarcoma (143B)
tumor tissue following treatment with each the targeted and untargeted doxorubicin-loaded
liposomal formulations at 5 mg/kg is displayed in Figure 7. Initially, the tumor demonstrates
an abundance of 143B cells (stained red) and connective tissue (stained blue) in the tumor
mass (left column). Particles coated with alendronate for targeting the tumor tissue resulted
in significant cell death (right column, top row). A lower level of cell death resulted in
tumors with uncoated nanoparticles (right column, middle row). Virtually no change in the
tumor infrastructure was observed in untreated animals (right column, bottom row). Micro-
CT analysis of these tumors immediately prior to resection (Figure S8) complements this
data, clearly demonstrating the enhanced efficacy of the targeted system relative to the
uncoated control. These observations suggest the potency of this approach to deliver the
payload in an efficacious manner to the 143B osteosarcoma solid tumor.
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3. Conclusion
LbL is a versatile platform to functionalize nanoparticles in ways that promote improved
biological performance. Prior art has established LbL as a means to impart protein-resistive,
long-circulating properties to nanoparticle systems, with a means to control biodistribution
of both the carrier and drug in a complex systemic environment. This investigation further
demonstrates the modularity of this approach to impart targeting capabilities to the
nanoparticle to diseased tissue to achieve enhanced treatment outcomes. We capture this
potential with the synthesis of osteotropic nanoparticles via incorporation of alendronate-
functionalized PAA as a means of surface modification of drug-loaded liposomes. Different
nanoparticle core substrates may be used for imaging and treatment for a variety of bone
diseases. While surgical resection of a primary tumor will continue to be the first-line of
treatment, subsequent treatment with the osteotropic nanoparticles has the potential to
decrease recurrance rates and increase successful outcomes. These functional nanoparticles
are also highly promising for future investigations towards treatment of bone-localized
metastases of invasive cancer cell types such as breast and lung cancer. The potential to
further generalize this approach towards the built-to-order manufacture of different targeted
delivery systems continues to provide much promise for LbL nanoparticles.
4. Experimental Section
PAA-Alendronate conjugation
Alendronate (Alfa-Aesar) was conjugated to poly(acrylic acid) (Sigma) through the primary
amine functional group of alendronate. Half of the free carboxyl end group of the
poly(acrylic acid) was targeted for coupling. As both of the reacting species were only
soluble in water, we have used water soluble 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride (DMTMM) as the coupling agent[12]. To perform the
coupling chemistry, alendronate (1.0 eq.) was added to a solution of poly(acrylic acid) (0.5
equivalents considering all carboxylic groups) in 100 mL water. The solution was stirred for
10 minutes after which DMTMM (2.0 equiv.) was added to the resulting solution. The
reaction was allowed to run for 12 hours at room temperature. After the reaction period, the
solution was dialyzed against water for 36 hours for complete removal of coupling agent and
unreacted alendronate. The dialyzed solution of alendronate-conjugated poly(acrylic acid)
was lyophilized to yield a white foam-like product in 65% yield. 1H NMR (in D2O): 1.33 –
1.9 ppm [broad signal, poly(acrylic acid)], 2.10–2.40 ppm [broad signal, poly(acrylic acid)],
2.88 ppm (2H, alendronate). The degree of conjugation was estimated according to the assay
protocol reported previously after the hydrolysis of the conjugate at pH 10 with 0.1M
NaOH[13]. The estimated degree of functionalization was found to be 43.2%.
LbL on QDs
Carboxyl-modified quantum dots (QD800, Life Technologies) were suspended in dilute
solution (~10uL stock in 1mL DI water) and injected in excess 10mL polyelectrolyte
(5mg/mL for PLL-Hydrochloride (4–15K, Sigma); 1mg/mL PAA450K-Alendronate) while
under agitation at 4°C. Each layer was incubated for ~30 minutes, prior to purification via
ultracentrifugation (12,500 RPM, 30m minutes – 1st layer required longer spins, subsequent
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purifications are much more expedient) and washing with DI water, repeated twice prior to
introduction to the subsequent polyelectrolyte. The final functionalized particle was re-
suspended in 1X PBS after the 2nd wash and filtered in a 0.45μm filter for further
experimentation.
Liposome synthesis
Liposomes were formulated at a mass ratio of 56:39:5 (DSPC:Cholesterol:POPG – all
purchased from Avanti Polar Lipids). These three components were dissolved in a 2:1
mixture of chloroform:methanol. A thin film of these materials was generated by rotary
evaporation at 40°C, 150 mbar for approximately 10 minutes. This film was allowed to
dessicate overnight for complete drying. Hydration of the lipid film was conducted at 65°C
under sonication in 300 mM citric acid buffer (pH 4) for 1 hour, after which they were
filtered through a 0.2 µm PES syringe filter and allowed to cool to room temperature. The
pH of the liposomal suspension was then adjusted to 6.5 by addition of 300 mM sodium
carbonate buffer to create a gradient between the exterior and interior compartments.
Doxorubicin (LC Laboratories) at a feed ratio of 3 mg drug to 50 mg lipids was then added
in a 0.9% sodium chloride solution to load via a pH gradient method. The final drug-loaded
system was subsequently purified out of the high salt buffers and any excess, unloaded drug
via centrifugal filtration (100K MWCO Millipore) and transferred to DI water for
subsequent functionalization via LbL. Blank liposomes were prepared in the same fashion;
however, no drug was added.
LbL on liposomes
Liposomes were diluted in 1 mL DI water (from a 50 mg batch prepared in a final
suspension of 5 mL DI water – use ~200 μL stock to 800 μL DI water) and injected in
excess polyelectrolyte under agitation at 4°C as previously described for QDs. Incubate for
~30 minutes, purify via ultracentrifugation at 10,000 RPM for ~10 minutes – repeat twice
prior to introduction to subsequent polyelectrolyte. The final, functionalized liposomal
system was filtered through a 0.45 μm filter and suspended in 1X PBS for further
experimentation.
Physicochemical characterization
Dynamic light scattering and zeta potential analysis was conducted in 10 mM sodium
chloride at 25°C using a Malvern ZS90 zeta-sizer. High-performance liquid chromatography
(Agilent technologies, 1:1 acetonitrile to pH 5 water mobile phase) and nanodrop
absorbance measurements (480nm) were performed to quantify doxorubicin concentrations
in the prepared samples. Cryo-TEM was conducted by imaging a frozen dilute sample of the
liposomal suspension at 120 kV.
In vitro Binding/Cytotoxicity
143B osteosarcoma cells and human mesenchymal stem cells were seeded in 96-well tissue
culture plates at a density of 1x103 cells/well and allowed to proliferate for 48 hours. PLL-
Cy5.5 labeled particles were quantified based on fluorescence, serially diluted in cell culture
media and added to the cells. After 24–48 hours, cells were washed 3X with PBS. Binding
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was measured by quantifying the amount of residual fluorescence in the well. Cytotoxicity
was measured using a standard MTT assay.
Fluorescence-activated cell sorting analysis
Measurements were performed using a BD LSRFortessa (BD biosciences, San Jose, CA).
PLL-Cy5.5 fluorescence was collected following excitation at 640 nm and detected at
710/50 nm (AF700 channel). Cell-association data presented as representative histogram
overlays of data collected in triplicate following 143B cell incubation with blank, PLL-
Cy5.5 coated, PAA-Alendronate functionalized LbL liposomes for 2 hours at 37°C in 96-
well plates. Final samples ran for analysis were washed 3X with optiMEM and trypsinized
immediately prior to introduction to the flow cytometer. Blue is the representative treatment;
red is the control sample without treatment.
Confocal Microscopy
Images were taken using a Nikon A1R Ultra-Fast Spectral Scanning Confocal Microscope
(Nikon instruments Inc., Melville, NY). 143B cells were seeded in a CELLview glass
bottom dish (Greiner Bio-One GmbH, Germany) at 1×105 cells per well and grown
overnight. Cells were then incubated with blank, PLL-Cy5.5 coated, PAA-Alendronate
functionalized LbL liposomes (or QDs) for 2 hours at 37°C. At the end of this period, cells
were washed, fixed via paraformaldehyde, permeabilized via Triton-1X, and stained with
phalloidin-568 for 30 minutes, followed by addition of DAPI for an additional 10 minutes,
after which they were washed 3X and imaged.
Xenograft development/targeting/treatment/monitoring – NCR nude
Cells were mixed in a 1:1 ratio with BD Matrigel™ Basement Membrane Matrix to a final
density of 5×106 cells/0.1 mL injection. 0.1mL injections of the matrix-cell suspension were
performed in each rear hind flank of NCR nude mice (Taconic). Tumors were allowed to
grow until a visible tumor was established, approximately 25 mm2 in tumor area prior to
treatment (determined via caliper measurements via the longest length and width
dimensions); for tumor targeting, xenografts were allowed to grow near terminal size (1 cm
in diameter) to reduce effects of EPR. Treatments were injected in 0.1mL 1X PBS at the
concentration and treatment regimen indicated in the figure legend. Imaging was performed
using whole-animal fluorescence imaging (IVIS, Xenogen, Caliper) at the time points
indicated pre- and post-administration at the given fluorescence filters. For targeting
experimentation, functionalized, fluorescent systems were administered at a radiant
efficiency of ~3x109 (700 channel)/~1x109 (800 channel) in a 0.1mL injection. This was
determined by imaging the vial prior to injection and diluting as necessary in 1X PBS.
Tissue harvest (liver, spleen, kidneys, heart, lungs, tumors, ‘gutted’ skeleton) was performed
at the terminal point of the experiment and imaged for fluorescence recovery against an
untreated control for auto-fluorescence determination. Tumor sizes for the remediation study
were monitored via caliper measurements, whereby areas based on the largest visible length
and width dimensions were measured. Depth proved challenging to reliably measure at early
time points due to skin thickness, therefore it was not included for a final volume
determination for real-time tumor size measurements.
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Pharmacokinetics (circulation) – immune-proficient BALB/c
Fluorescent systems (PLL-Cy5.5 coated LbL-targeted empty liposomes) were administered
in 0.1mL 1X PBS injections in BALB/c mice (Taconic) at a relative concentration of ~3x109
(700 channel)/~1x109 (800 channel) in a 0.1mL injection, based on fluorescence in the IVIS
prior to injection. Mice were imaged pre- and post-nanoparticle administration using whole-
animal fluorescence imaging (IVIS, Xenogen, Caliper) at the time points indicated and at the
given fluorescent filters. Retro-orbital bleeding was performed in a cohort of injected mice
to determine the serum half-life of the particles, presented on the basis of fluorescence
recovery in these isolated blood samples (~0.1mL blood/time point done in 3 different mice
for each time point plotted). Fluorescence recovery was determined by imaging in the IVIS
immediately following isolation and dilution 1:1 in EDTA to prevent coagulation. Final data
is normalized to an untreated control blood sample to remove artifacts of auto-fluorescence.
The data was fit to a two-compartment model (two-phase decay in PRISM®), from which
the fast and slow half-lives characterizing the data were extracted.
Histology
Tumors were resected at the terminal point of experimentation and fixed in 4%
paraformaldehyde (PFA) for 48 hours and transferred to 70% ethanol until processed. Tissue
was embedded in paraffin wax and sections were stained with routine hematoxylin and eosin
(H&E) and Masson’s trichrome stain.
Statistical Analysis
Experiments were performed in triplicates, or otherwise indicated. Data were analyzed using
descriptive statistics, single-factor analysis of variance (ANOVA), and presented as mean
values ± standard deviation (SD) from three to eight independent measurements. Statistical
comparisons between different treatments were assessed by two-tailed t tests or one-way
ANOVA assuming significance at P < 0.05.
Supplementary Material
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Bone-targeted nanoparticles are manufactured via Layer-by-Layer electrostatic
adsorption of an alendronate-functionalized polyelectrolyte, poly(acrylic acid), on a
nanoparticle substrate. High levels of bone specificity and efficacy against an
osteosarcoma xenograft tumor model demonstrate this approach as an attractive, modular
method for designing systems with tissue specificity for enhanced treatment outcomes.
Morton et al. Page 12
Adv Healthc Mater. Author manuscript; available in PMC 2015 April 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Achieving bone tissue level specificity of LbL coated nanoparticles
(A) Aqueous anionic polyelectrolyte, poly(acrylic acid) [PAA, MW 450K], functionalized
with the (B) bisphosphonate targeting moiety, alendronate [for high specificity to
hydroxyapatite in bone], to yield (C) the aqueous, ligand-functionalized polymer at 40%
side-chain functionalization (Figure S1), which is used for complementary, iterative
adsorption to the polycationic component (poly-L-lysine, PLL) in the film on the NP
substrate, schematically illustrated in (D).
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Figure 2. in vitro assessment of LbL-targeted QD NPs incubated with 143B osteosarcoma cells
(A) Confocal microscopy of 143B cells incubated with the LbL-targeted QD705 core NPs for
2 hours. Blue staining representative of a Hoescht nuclear stain, green representative of a
phalloidin stain of the actin filamentous cell structure, and red representative of the
nanoparticle fluorescence (QD705 fluorescence). Scale bar representative of 20µm. (B)
Binding and relative cytotoxicity of 3 bilayer [PLL/PAA-Alendronate] LbL-targeted QD800
core NPs following incubation for 2 hours in 143B cells. Fluorescence emission data
corresponds to that of the nanoparticle core (QD800).
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Figure 3. in vivo evaluation of LbL-targeted QD800 core NPs
(A) Representative live-animal imaging of LbL-targeted QD800 core NPs following systemic
administration to 143B osteosarcoma xenograft-bearing NCR nude mice. Imaging
conducted at λex = 640 nm, λem = 800 nm for up to 8 days. Hind-flank xenografts identified
in the pre-injection image; arrows at 5 minutes and 9 hours indicate binding to native bone
tissue. (B) Quantification of fold tumor-specific accumulation normalized to tissue auto-
fluorescence pre-injection for the systemically administered LbL-targeted QD800 core NPs,
as visualized in (A). n = 3 mice (6 tumors); data presented as mean +/− SEM. (C)
Biodistribution data corresponding to endpoint of (A) (quantified as percent recovered
fluorescence following harvest of relevant tissue after 8 days post-administration). n = 3
mice (6 tumors); data presented as mean +/− SEM. (D) Co-localization of QD800 NP core
with LbL-film containing labeled PAA-Alendronate700; top row [PAA-Alendronate700
channel] – imaging conducted at λex = 640 nm, λem = 700 nm, bottom row [QD800 channel]
- imaging conducted at λex = 640 nm, λem = 800 nm.
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Figure 4. in vitro evaluation of LbL-targeted liposomal NPs in 143B cells
(A) Cryo-TEM of LbL-targeted doxorubicin-loaded liposomal NPs. Scale bar representative
of 200 nm. (B) Binding (2 hour incubation) and relative cytotoxicity (48 hour incubation) of
LbL-targeted empty liposomal NPs over a range of concentrations, based on fluorescence, in
143B cells (λex = 675 nm, λem = 710 nm; tracked using PLL700 as cationic component in
LbL film). (C) Confocal microscopy of 143B cells incubated with the LbL-targeted empty
liposomal NPs [tracked via PLL700 polycationic component in LbL film] for 2 hours. Blue
staining representative of a Hoescht nuclear stain, green representative of a phalloidin stain
of the actin filamentous cell structure, and red representative of the nanoparticle
fluorescence (PLLCy5.5 polymer shell fluorescence). Scale bar representative of 10 μm. (D)
Representative cell-associated NP fluorescence following a 2 hour incubation of 143B cells
with the LbL-targeted empty liposomal NPs. (E) in vitro cytotoxicity of LbL-targeted
doxorubicin-loaded liposomal NPs and the corresponding (F) uncoated doxorubicin-loaded
liposomal control following 48 hour (blue) and 72 hour (red) incubation periods over a
range of doxorubicin concentrations.
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Figure 5. Biological evaluation of LbL-targeted empty liposomal NPs
LbL-targeted empty liposomal NPs tracked via PLL700 polycationic component in surface
coating. Circulation data in (A) normalized to % remaining particles recovered, on the basis
of fluorescence [λex = 640 nm, λem = 700 nm], immediately following systemic
administration to immune proficient BALB/c mice; data presented as mean +/− SEM (n =
3). Two-compartment model fit to determine half-lives displayed. Data includes background
subtraction of blood auto-fluorescence. (B) Quantification of fold tumor-specific
accumulation normalized to tissue auto-fluorescence pre-injection for the systemically
administered LbL-targeted blank liposomal core NPs to 143B xenograft-bearing NCR nude
mice; data presented as mean +/− SEM (n = 3). (C) Biodistribution data corresponding to
endpoint of (B) (quantified as percent recovered fluorescence [λex = 640 nm, λem = 700 nm]
following harvest of relevant tissue after 100 hours post-systemic administration); data
presented as mean +/− SEM (n = 3).
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Figure 6. 143B xenograft tumor remediation following treatment with doxorubicin-loaded
liposomal formulations
(A) in vivo tumor remediation of 143B xenografts in NCR nude mice for LbL-targeted
doxorubicin-loaded liposomal NPs, against untreated and uncoated doxorubicin-liposomal
NPs. Untreated control xenografts were sacrificed 19 days post-inoculation of xenograft due
to tumor burden exceeding 1 cm. Untargeted and targeted Dox-liposomal formulations were
sacked at 30 days post-inoculation following a dose-escalation study with the following
treatment regimen: day 10 at 1 mg/kg, day 17 at 2 mg/kg, day 24 at 3 mg/kg. Terminal point
shown with final tumor area displayed in (B). Statistics are from an unpaired t-test, two-
tailed to compare the untargeted and targeted formulations at each time point. Data
presented as mean +/− SEM; n = 4. (C) Caliper measurements for in vivo tumor remediation
with repeated dosing of 5 mg/kg for both targeted and untargeted formulations at 22 days,
28 days, and 35 days post-inoculation (displayed as day 0, day 6, and day 13 in (C)).
Statistics are from an unpaired t-test, two-tailed to compare the untargeted and targeted
formulations; *p < 0.05; **p < 0.01; ***p < 0.001. Data presented as mean +/− SEM; n = 4.
Resection of tumors from terminal point of (C), n = 4 for each group, displayed from the
final caliper measurement.
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Figure 7.
Representative histology of 143B tumors harvested at 18 days post-treatment corresponding
to the terminal point in Figure 6C. (left column) tumors prior to treatment; (right column)
tumors at the 18 day terminal point post treatment of 3 repeated injections at 5 mg/kg
doxorubicin. (top row) tumors treated with PAA-Alendronate coated doxorubicin-loaded
liposomes, (middle row) uncoated dox-loaded liposomes, and (bottom row) untreated
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animals. Masson’s trichrome stain – red = 143B osteosarcoma cells, blue = connective
tissue; scale bars representative of 100 µm.
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